Evaluation of pain after intra-articular botulinum toxin injections in carpometacarpal osteoarthritis of the thumb

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517280-23-00

Enrollment

Registered

2024-10-18

Start date

2021-04-01

Completion date

2025-05-14

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the first carpometacarpal joint

Brief summary

Evolution of the initial pain by Visual Analogue Scale compared to that measured at 3 months after the injection. Score from 0 to 10. 0 corresponds to the absence of pain and 10 to the maximum imaginable pain.

Interventions

DRUGProduct Name : NT 201 Dosage Form : Powder for Solution for lnjection Strength : Placebo 100 Unit (25) USP ges. Packaging : lnjection Vial Manufacturing site(s) : Merz Pharma GmbH & Co. KGaA

DRUGWerk Dessau

DRUGAm Pharmapark

DRUGD-06861 Dessau/ Roßlau Testing site(s) : Merz Pharma GmbH & Co. KGaA

DRUGD-06861 Dessau/ Roßlau

DRUGXEOMIN 50 unités

DRUGpoudre pour solution injectable

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Evolution of the initial pain by Visual Analogue Scale compared to that measured at 3 months after the injection. Score from 0 to 10. 0 corresponds to the absence of pain and 10 to the maximum imaginable pain.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026